Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F14%3A10291072" target="_blank" >RIV/00064165:_____/14:10291072 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1016/S1470-2045(14)70051-8" target="_blank" >http://dx.doi.org/10.1016/S1470-2045(14)70051-8</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/S1470-2045(14)70051-8" target="_blank" >10.1016/S1470-2045(14)70051-8</a>

Result language
angličtina
Original language name
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study
Original language description
Background The orally available BRAF kinase inhibitor vemurafenib, compared with dacarbazine, shows improved response rates, progression- free survival (PFS), and overall survival in patients with metastatic melanoma that has a BRAF(V600) mutation. We assessed vemurafenib in patients with advanced metastatic melanoma with BRAF(V600) mutations who had few treatment options. Methods In an open-label, multicentre study, patients with untreated or previously treated melanoma and a BRAF(V600) mutation received oral vemurafenib 960 mg twice a day. The primary endpoint was safety. All analyses were done on the safety population, which included all patients who received at least one dose of vemurafenib. This report is the third interim analysis of this study.This study is registered with ClinicalTrials.gov, number NCT01307397.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FO - Dermatology and venereology
OECD FORD branch
—

Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)